The Canadian Nosocomial Infection Surveillance Program

Vancomycin - Resistant Enterococci (VRE) Surveillance

CNISP VRE Surveillance

Presentation

PDF Version

1998 to 2005

Marianna Ofner, Lynn Johnston, Michael Mulvey, Andrew Simor, David Boyd, John Conly, Anne Matlow, Jacob Stegenga, Romeo Hizon, Tim Du, Jennifer Campbell and John Embil

Surveillance results 1999-2005

• From October 1998 to 2005
  • 3039 new cases of VRE were identified
• Infection rate = 6.3% (n=189)
• Rates increased over 7 years of surveillance from:
  • 0.37 to 1.32 / 1,000 patient admissions
  • 5.34 to 15.5 / 100,000 patient days
  • 1.1 to 3.1 / 100 enterococcal isolates*
    *based on 8 CNISP sites

VRE Incidence Rates per 100 enterococcal isolates

VRE per 1,000 patient admissions

VRE Rate per 1,000 patient admissions by Region

VRE Infections (n=189)

Molecular Characteristics
2434 VRE Analyzed

Conclusions

• Over 7 years of surveillance, the rate rose due primarily to colonizations
• Compared to 2004 NNIS rates in the US of 12%, rates in Canada of 3.3% remain significantly lower.
• 1/3 of the cases have occurred in 2005
• Infection rates have remained stable (6.3%)
• While in the past rates were increasing in the West, more recent data show that rates are increasing in all regions of Canada.